IDEXX Laboratories, Inc. $IDXX Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 75.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,631 shares of the company’s stock after selling 32,794 shares during the quarter. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $5,973,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Beacon Investment Advisory Services Inc. grew its stake in IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after acquiring an additional 6,710 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after purchasing an additional 8,845 shares during the last quarter. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $1,966,000. Diversified Trust Co. grew its holdings in IDEXX Laboratories by 223.5% in the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after buying an additional 2,901 shares in the last quarter. Finally, Mirabella Financial Services LLP grew its holdings in shares of IDEXX Laboratories by 156.2% in the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock valued at $2,806,000 after purchasing an additional 2,683 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IDXX. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $551.50 on Monday. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company’s 50 day moving average is $558.79 and its two-hundred day moving average is $614.13. The company has a market cap of $43.50 billion, a PE ratio of 40.61, a P/E/G ratio of 3.02 and a beta of 1.56. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.